Dobney Hypertension Centre, Medical School, University of Western Australia, Perth, Australia.
Medical School, University of Western Australia, Perth, Australia.
Curr Hypertens Rep. 2021 Dec 9;23(12):44. doi: 10.1007/s11906-021-01161-6.
PURPOSE OF REVIEW: To provide an overview of the associations between elevated blood pressure and lipoprotein (a) and possible causal links, as well as data on the prevalence of elevated lipoprotein (a) in a cohort of hypertensive patients. RECENT FINDINGS: Elevated lipoprotein (a) is now considered to be an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Despite this, there are limited data demonstrating an association between elevated lipoprotein (a) and hypertension. Further, there is limited mechanistic data linking lipoprotein (a) and hypertension through either renal impairment or direct effects on the vasculature. Despite the links between lipoprotein (a) and atherosclerosis, there are limited data demonstrating an association with hypertension. Evidence from our clinic suggests that ~ 30% of the patients in this at-risk, hypertensive cohort had elevated lipoprotein (a) levels and that measurement of lipoprotein (a) maybe useful in risk stratification.
目的综述: 脂蛋白(a)与高血压之间的关联及可能的因果关系,并提供高血压患者队列中脂蛋白(a)升高的患病率数据。
最新发现: 脂蛋白(a)现在被认为是动脉粥样硬化性心血管疾病和钙化主动脉瓣疾病的独立和因果危险因素。尽管如此,目前仅有有限的数据表明脂蛋白(a)升高与高血压之间存在关联。此外,通过肾脏损害或对血管的直接作用将脂蛋白(a)与高血压联系起来的机制数据也很有限。尽管脂蛋白(a)与动脉粥样硬化之间存在关联,但目前仅有有限的数据表明其与高血压有关。我们临床的证据表明,在这个高危、高血压的患者队列中,约有 30%的患者脂蛋白(a)水平升高,脂蛋白(a)的测量可能有助于风险分层。
Curr Hypertens Rep. 2021-12-9
Prog Cardiovasc Dis. 2020-6-8
Curr Opin Cardiol. 2016-7
Trends Pharmacol Sci. 2019-2-4
Curr Opin Lipidol. 2018-6
Curr Opin Cardiol. 2024-1-1
Lipids Health Dis. 2025-5-24
Int J Mol Sci. 2023-8-29
Diagnostics (Basel). 2023-7-12
Heart Fail Rev. 2023-11
Curr Opin Endocrinol Diabetes Obes. 2021-4-1
Curr Opin Lipidol. 2019-12
J Am Coll Cardiol. 2019-7-9
Eur Heart J. 2020-6-21
Clin Res Cardiol Suppl. 2019-4
Crit Rev Clin Lab Sci. 2017-12-20